Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades.


Journal

Oxidative medicine and cellular longevity
ISSN: 1942-0994
Titre abrégé: Oxid Med Cell Longev
Pays: United States
ID NLM: 101479826

Informations de publication

Date de publication:
2020
Historique:
received: 06 04 2020
revised: 07 06 2020
accepted: 26 06 2020
entrez: 25 8 2020
pubmed: 25 8 2020
medline: 9 6 2021
Statut: epublish

Résumé

Inhibition of either P2Y12 receptor or the nucleotide-binding oligomerization domain- (NOD-) like receptor pyrin domain containing 3 (NLRP3) inflammasome provides cardioprotective effects. Here, we investigate whether direct NLRP3 inflammasome inhibition exerts additive effects on myocardial protection induced by the P2Y12 receptor antagonist Ticagrelor. Ticagrelor (150 mg/kg) was orally administered to rats for three consecutive days. Then, isolated hearts underwent an ischemia/reperfusion (30 min ischemia/60 min reperfusion; IR) protocol. The selective NLRP3 inflammasome inhibitor INF (50 

Identifiants

pubmed: 32832010
doi: 10.1155/2020/9219825
pmc: PMC7424511
doi:

Substances chimiques

Inflammasomes 0
NLR Family, Pyrin Domain-Containing 3 Protein 0
Platelet Aggregation Inhibitors 0
Ticagrelor GLH0314RVC

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9219825

Informations de copyright

Copyright © 2020 Claudia Penna et al.

Déclaration de conflit d'intérêts

The authors declare that they have no conflicts of interest.

Références

Thromb Haemost. 2015 May;113(5):1035-45
pubmed: 25716539
J Nutr Biochem. 2017 Apr;42:160-171
pubmed: 28189916
Curr Med Chem. 2018;25(11):1294-1310
pubmed: 28403789
J Pharmacol Exp Ther. 2016 Oct;359(1):45-53
pubmed: 27440421
Biochem Pharmacol. 2013 Jan 15;85(2):257-64
pubmed: 23103566
Am J Physiol Heart Circ Physiol. 2005 Apr;288(4):H1900-8
pubmed: 15563525
Sci Rep. 2016 Jun 09;6:27594
pubmed: 27277195
Cardiovasc Drugs Ther. 2016 Apr;30(2):229-32
pubmed: 26780906
J Cardiovasc Pharmacol Ther. 2013 May;18(3):251-62
pubmed: 23233653
P T. 2018 Jun;43(6):352-357
pubmed: 29896034
Basic Res Cardiol. 2018 Jul 10;113(5):32
pubmed: 29992382
Basic Res Cardiol. 2009 Jul;104(4):390-402
pubmed: 19030912
J Cardiovasc Pharmacol. 2018 Dec;72(6):259-269
pubmed: 29979350
Cardiovasc Drugs Ther. 2012 Jun;26(3):227-37
pubmed: 22392184
Exp Biol Med (Maywood). 2014 Jun;239(6):647-62
pubmed: 24668550
J Cardiovasc Pharmacol Ther. 2017 Nov;22(6):574-578
pubmed: 28399648
Basic Res Cardiol. 2018 Aug 17;113(5):39
pubmed: 30120595
J Med Chem. 2017 May 11;60(9):3656-3671
pubmed: 28410442
Oxid Med Cell Longev. 2016;2016:5271251
pubmed: 28053692
Blood Rev. 2015 May;29(3):153-62
pubmed: 25468720
Pharmacol Rev. 2014 Oct;66(4):1142-74
pubmed: 25261534
Oxid Med Cell Longev. 2016;2016:3480637
pubmed: 26788246
J Cardiovasc Pharmacol Ther. 2019 Jan;24(1):11-17
pubmed: 29991269
Br J Pharmacol. 2016 Apr;173(7):1163-78
pubmed: 26758983
Cardiovasc Res. 2019 Jun 1;115(7):1156-1166
pubmed: 30590395
Arterioscler Thromb Vasc Biol. 2015 Aug;35(8):1805-14
pubmed: 26044583
Biochem Biophys Res Commun. 2012 Feb 24;418(4):754-8
pubmed: 22306816
J Cardiovasc Pharmacol. 2019 Oct;74(4):271-275
pubmed: 31356546
J Clin Invest. 2015 Apr;125(4):1379-87
pubmed: 25831442
Cardiovasc Drugs Ther. 2013 Oct;27(5):403-12
pubmed: 23832692
Circulation. 2016 Nov 29;134(22):1708-1719
pubmed: 27789556
J Am Coll Cardiol. 2014 Mar 11;63(9):872-7
pubmed: 24291273
Br J Pharmacol. 2018 Oct;175(19):3741-3746
pubmed: 30047983
Mol Med. 2016 Mar;21(1):1025-1037
pubmed: 26623925
J Cardiovasc Pharmacol Ther. 2014 Mar;19(2):209-19
pubmed: 24414167
PLoS One. 2017 Mar 1;12(3):e0172575
pubmed: 28249038
ChemMedChem. 2016 Aug 19;11(16):1790-803
pubmed: 26990578
Cardiovasc Drugs Ther. 2016 Dec;30(6):539-550
pubmed: 27830382
Basic Res Cardiol. 2009 Mar;104(2):189-202
pubmed: 19242644
J Am Coll Cardiol. 2014 Jun 17;63(23):2503-2509
pubmed: 24768873
J Cardiovasc Pharmacol Ther. 2019 Jul;24(4):371-376
pubmed: 30744423
Expert Opin Investig Drugs. 2000 Nov;9(11):2519-35
pubmed: 11060817
J Med Chem. 2014 Dec 26;57(24):10366-82
pubmed: 25418070
Antioxid Redox Signal. 2011 Mar 1;14(5):833-50
pubmed: 20649460
Annu Rev Physiol. 2000;62:79-109
pubmed: 10845085
J Cardiovasc Pharmacol. 2019 Apr;73(4):215-222
pubmed: 30747785
Basic Res Cardiol. 2017 Nov 15;113(1):2
pubmed: 29143177
Sheng Li Xue Bao. 2007 Oct 25;59(5):593-600
pubmed: 17940699
Am J Physiol Heart Circ Physiol. 2001 Dec;281(6):H2585-9
pubmed: 11709426
Antioxid Redox Signal. 2013 Feb 10;18(5):556-99
pubmed: 22668069
Br J Pharmacol. 2015 Apr;172(8):1913-32
pubmed: 25205071
Biochem Biophys Res Commun. 2016 Jan 22;469(4):1012-20
pubmed: 26706279
Circ Res. 2015 Jul 31;117(4):376-87
pubmed: 26129975
Curr Med Chem. 2020;27(2):230-239
pubmed: 30907304
Cardiovasc Res. 2004 Feb 15;61(3):448-60
pubmed: 14962476

Auteurs

Claudia Penna (C)

Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

Manuela Aragno (M)

Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

Alessia Sofia Cento (AS)

Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

Saveria Femminò (S)

Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

Isabella Russo (I)

Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

Federica Dal Bello (FD)

Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.

Fausto Chiazza (F)

Department of Drug Science and Technology, University of Turin, Turin, Italy.

Debora Collotta (D)

Department of Drug Science and Technology, University of Turin, Turin, Italy.

Gustavo Ferreira Alves (GF)

Department of Drug Science and Technology, University of Turin, Turin, Italy.

Massimo Bertinaria (M)

Department of Drug Science and Technology, University of Turin, Turin, Italy.

Elisa Zicola (E)

Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

Valentina Mercurio (V)

Department of Translational Medical Sciences, Federico II University, Naples, Italy.

Claudio Medana (C)

Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.

Massimo Collino (M)

Department of Drug Science and Technology, University of Turin, Turin, Italy.

Pasquale Pagliaro (P)

Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH